Core Viewpoint - Huahong Semiconductor plans to acquire controlling stake in Shanghai Huahong Microelectronics to resolve industry competition issues related to its IPO commitments [1][4][6] Group 1: Acquisition Details - The acquisition involves assets related to the 65/55nm and 40nm processes, which are currently in competition with Huahong's existing operations [1][4] - The transaction is classified as a related party transaction but will not change the actual controller of the company and does not constitute a restructuring [1][4] - The acquisition is part of Huahong's commitment made during its IPO to eliminate competition with Huahong Microelectronics [4][6] Group 2: Market Reaction - Following the announcement, Huahong's stock experienced a decline, with a drop of over 9% on the Hong Kong market [2] - Investors expressed concerns that the acquisition targets mature process assets rather than advanced ones, leading to a perception that the acquisition is below expectations [3][6] Group 3: Industry Context - Huahong is the second-largest wafer foundry in China and is expanding its production capabilities from 8-inch to 12-inch wafers to meet growing market demand [7][8] - The company aims to enhance its 12-inch production line capacity and diversify its product offerings based on various technology nodes [8] - The acquisition of Huahong Microelectronics' 12-inch production line is expected to address capacity shortfalls and improve profitability through synergies [8]

Core Viewpoint - Huahong Semiconductor announced a significant acquisition to resolve competition issues related to its IPO commitments by acquiring controlling stakes in Shanghai Huahong Microelectronics, which operates assets that compete with Huahong's existing operations in the 65/55nm and 40nm nodes [1][5][7]. Group 1: Acquisition Details - The acquisition involves the purchase of equity corresponding to the assets operated by Huahong Micro that are in direct competition with Huahong's existing operations [1][5]. - The transaction is classified as a related party transaction but will not result in a change of actual control of the company and does not constitute a restructuring [1][5]. - The acquisition aims to address the same-industry competition issues that arose during Huahong's IPO process, as outlined in a commitment letter from Huahong Group [5][6]. Group 2: Market Reaction - Following the announcement, Huahong's A-shares were suspended from trading, while its Hong Kong shares experienced a decline of over 9% on the opening day after the announcement [3][4]. - Investor feedback indicated disappointment as the acquisition targets mature process assets rather than advanced process technologies, leading to concerns about the perceived value of the acquisition [3][7]. Group 3: Strategic Importance - The acquisition is seen as a critical step for Huahong Group to fulfill its IPO commitments and eliminate internal competition, thereby consolidating resources [7][10]. - The integration of Huahong Micro's 12-inch production capacity is expected to enhance Huahong's overall production capabilities and profitability, addressing existing capacity shortfalls [9][10]. Group 4: Production Capacity Expansion - Huahong has been expanding its production capabilities from 8-inch to 12-inch wafers, with a focus on increasing the output of its 12-inch production lines to meet growing market demand [9][10]. - The revenue contribution from 12-inch wafers has been increasing, with a notable rise from $233 million in the previous year to $334 million in the second quarter of 2025 [9].

Core Viewpoint - Huahong Semiconductor (688347) announced a restructuring with Huahong Micro to resolve competition issues related to its IPO commitments, with the stock price of Huahong Semiconductor falling by 6.2% in Hong Kong [2] Group 1: Company Restructuring - Huahong Semiconductor plans to acquire controlling interest in Shanghai Huahong Microelectronics through a combination of issuing shares and cash payments, focusing on assets that overlap in the 65/55nm and 40nm technology nodes [2] - The acquisition is still in the planning stage, with initial discussions involving several investment entities, and the final transaction details will be disclosed in the restructuring proposal [2] Group 2: Production Capacity and Technology - Huahong Semiconductor operates three 8-inch wafer fabs and two 12-inch specialty process fabs, including the world's first 12-inch power device foundry line, while Huahong Micro has the first fully automated 12-inch IC manufacturing line in mainland China [3] - The company focuses on specialty processes, while Huahong Micro targets advanced logic processes, with some business overlap in the 65/55nm nodes [3] Group 3: Financial Performance - In Q1, Huahong Group ranked sixth in revenue with $1.01 billion, a 3% decline quarter-over-quarter; however, in Q2, the company reported $566 million in sales, an 18.3% year-over-year increase, and a net profit of $8 million, up 19.2% [4] - The gross margin reached 10.9% due to increased capacity utilization offsetting depreciation costs, with projected Q3 sales expected to be between $620 million and $640 million, and gross margin estimated between 10% and 12% [4] Group 4: Market Demand and Future Outlook - Recent indications show stabilization in downstream demand, with strong growth in AI applications and positive short-term performance in consumer electronics due to policy stimuli [5] - The company aims to leverage existing capacity while enhancing process capabilities, with a long-term need for capacity expansion, particularly in more promising specialty process nodes and platforms [6]

8月18日，南下资金净买入港股13.86亿港元。其中： 净买入中国人寿6.72亿港元、阿里巴巴-W 6.17亿港元、华虹半导体3.89亿港元、腾讯控股2.99亿港元、 东方甄选2.99亿港元、中芯国际1.62亿港元；净卖出盈富基金64.13亿港元、恒生中国企业14.45亿港元、 南方恒生科技5.73亿港元、小米集团-W 2.1亿港元、快手-W 1.49亿港元。 北水关注个股 中国人寿：据天眼查工商信息显示，近日，长沙聚财壹号股权投资基金合伙企业（有限合伙）成立，执 行事务合伙人为国寿置业投资管理有限公司，出资额8.01亿人民币，经营范围包括以私募基金从事股权 投资、投资管理、资产管理等活动。股权全景穿透图显示，该基金由财信吉祥人寿保险股份有限公司、 中国人寿旗下国寿置业投资管理有限公司共同出资。 据统计，南下资金已连续5日净买入中芯国际，共计10.3549亿港元；连续3日净买入阿里巴巴，共计 25.2673亿港元。 华虹半导体：中金发表研究报告指出，华虹半导体次季营收5.66亿美元，按年升18.3%，符合此前指引 的5.5至5.7亿美元区间；毛利率10.9%，按年升0.4个百分点，超出此前指引7%至9%；归母 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 HUA HONG SEMICONDUCTOR LIMITED 華虹半導體有限公司 （於香港註冊成立之有限公司） （股份代號：01347） 中國上海，二零二五年八月十八日 於本公告日期，本公司董事分別為： 執行董事 唐均君（ 董事會主席 ） 白鵬（ 總裁 ） 非執行董事 葉峻 孫國棟 陳博 熊承艷 獨立非執行董事 張祖同 王桂壎太平紳士 封松林 董事會會議日期通知 華虹半導體有限公司（「本公司」）特此通知，本公司謹訂於二零二五年八月二十八 日（星期四）上午十時舉行董事會會議，以商討下列事項： 承董事會命 華虹半導體有限公司 董事會主席兼執行董事 唐均君先生 1. 考慮及批准刊發本公司及其附屬公司截至二零二五年六月三十日止未經審核 中期業績；及 2. 商議任何其他事項。 ...

格隆汇8月18日丨华虹半导体(01347.HK)公布，公司谨订于2025年8月28日(星期四)上午十时举行董事会 会议，以商讨下列事项：1.考虑及批准刊发公司及其附属公司截至2025年6月30日止未经审核中期业 绩；及2.商议任何其他事项。 ...

Market Overview - The Hong Kong stock market experienced a pullback after an initial rise, with the Hang Seng Index closing down 0.37% at 25,176.85 points and a total turnover of HKD 312.78 billion [1] - The market is currently in a phase of volatility with a lack of clear trading themes, as significant domestic and international events are awaited [1] Blue-Chip Stocks Performance - JD Health (06618) led the blue-chip stocks with an increase of 8.41%, closing at HKD 66.4, contributing 9.14 points to the Hang Seng Index [2] - Other notable performers included Alibaba Health (00241) up 3.56% and ZTO Express (02057) up 3.14%, while Kang Shifu Holdings (00322) and China Shenhua (01088) saw declines of 3.23% and 2.65% respectively [2] Sector Highlights - The film and entertainment sector showed strong performance, with companies like Lingmeng Film (09857) and Yuewen Group (00772) rising 21.33% and 15.34% respectively [3][4] - The brokerage sector continued its upward trend, with notable gains from CITIC Securities (06030) and Guotai Junan (01456) [4] Pharmaceutical Sector - The pharmaceutical sector saw a resurgence, with companies like Zhonghui Biopharma (02627) and Junshi Biosciences (01877) increasing by 13.4% and 13.25% respectively [5] - Upcoming academic conferences such as WCLC and ESMO are expected to catalyze interest in Chinese innovative drugs, with several companies set to present significant clinical trial results [6] Notable Stock Movements - Yasheng Life Services (03319) reported a profit warning, leading to a 13.06% increase in its stock price [7] - Great Wall Motors (02333) saw a strong performance with a 10.21% rise following the pre-sale of its new model [8] - Xtep International (01368) and ZTE Corporation (00763) also experienced significant gains of 7.33% and 7.22% respectively [9][10] - Conversely, Hua Hong Semiconductor (01347) faced a decline of 6.2% due to news of a planned acquisition [11] and Standard Chartered Group (02888) dropped 5.29% amid allegations of illegal payments [12]

Market Overview - The Hong Kong stock market experienced a pullback after an initial rise, with the Hang Seng Index closing down 0.37% at 25,176.85 points and a total trading volume of HKD 312.78 billion [1] - The market is currently in a phase of volatility with a lack of clear trading themes, as significant domestic and international events are awaited [1] Blue-Chip Stocks Performance - JD Health (06618) led the blue-chip stocks, rising 8.41% to HKD 66.4, contributing 9.14 points to the Hang Seng Index [2] - Other notable performers included Alibaba Health (00241) up 3.56%, and ZTO Express (02057) up 3.14%, while China Shenhua (01088) and Master Kong (00322) saw declines [2] Sector Highlights - The technology sector showed mixed results, with Tencent down 0.84% and Alibaba up 0.42% [3] - The film and entertainment sector saw strong gains, with companies like Lingmeng Media (09857) and Reading Group (00772) rising significantly [3][4] - The brokerage sector continued its upward trend, with notable increases in shares of CITIC Securities (06030) and Guotai Junan (01456) [4] Pharmaceutical Sector - Several pharmaceutical stocks rose, driven by upcoming academic conferences such as WCLC and ESMO, which are expected to reveal new data [5][6] - Notable gainers included Zhonghui Biotech (02627) and Junshi Biosciences (01877), both seeing significant increases in their stock prices [5] Noteworthy Stock Movements - Yasheng Services (03319) announced a profit warning, leading to a 13.06% increase in its stock price [7] - Great Wall Motors (02333) saw a strong performance with a 10.21% rise following the pre-sale of its new model [8] - Xtep International (01368) reported a 7.33% increase after announcing its mid-year results [9] - ZTE Corporation (00763) rose 7.22% amid growing demand for AI data centers [10] - Hua Hong Semiconductor (01347) fell 6.2% due to news of a planned acquisition [11] - Standard Chartered (02888) faced a decline of 5.29% following allegations of illegal payments [12]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 HUA HONG SEMICONDUCTOR LIMITED 華虹半導體有限公司 唐均君（ 董事會主席 ） 白鵬（ 總裁 ） 非執行董事 董事會會議日期通知 華虹半導體有限公司（「本公司」）特此通知，本公司謹訂於二零二五年八月二十八 日（星期四）上午十時舉行董事會會議，以商討下列事項： 承董事會命 華虹半導體有限公司 董事會主席兼執行董事 唐均君先生 中國上海，二零二五年八月十八日 於本公告日期，本公司董事分別為： 執行董事 （於香港註冊成立之有限公司） （股份代號：01347） 葉峻 孫國棟 陳博 熊承艷 獨立非執行董事 張祖同 王桂壎太平紳士 封松林 1. 考慮及批准刊發本公司及其附屬公司截至二零二五年六月三十日止未經審核 中期業績；及 2. 商議任何其他事項。 ...

Core Viewpoint - Huahong Semiconductor plans to acquire controlling stake in Shanghai Huahong Microelectronics to resolve industry competition issues related to its IPO commitments, while also raising funds through share issuance and cash payment [1][3]. Group 1: Acquisition Details - The acquisition targets assets related to the 65/55nm and 40nm processes, which are in direct competition with Huahong's existing operations [1][2]. - The transaction is classified as a related party transaction but will not change the actual controller of the company and does not constitute a restructuring [1][3]. - The acquisition is currently in the planning stage, with initial discussions involving several investment funds and companies [2]. Group 2: Market Reaction - Following the announcement, Huahong's stock price on the Hong Kong market fell by over 9%, despite a previous increase of 16.6% in the week prior [1]. - Some investors expressed concerns that the acquisition involves mature process assets rather than advanced ones, leading to a perception that the deal is below expectations [1]. Group 3: Industry Context - The acquisition is part of Huahong's commitment made during its IPO to eliminate competition with Huahong Microelectronics, which operates similar process nodes [3][4]. - Huahong's manufacturing capabilities include the first fully automated 12-inch IC production line in mainland China, with a monthly capacity of 38,000 wafers [3]. - The company aims to enhance its 12-inch production capacity to meet the growing demand in the semiconductor market, with a focus on specialty processes [6][7]. Group 4: Future Prospects - The acquisition is expected to address capacity shortfalls and improve profitability through synergies [7]. - Huahong's revenue from 12-inch wafers has been increasing, with a significant rise in revenue contribution from this segment in the second quarter of 2025 [6].